Alexander Maxwell
Value, growth, long-term horizon, biotech

AEterna Zentaris: An Interesting Investment With Long-Term Growth Potential

AEterna Zentaris (NASDAQ:AEZS) is a small cap drug development company. Like many drug development companies, it has had its share of success and failures over the years. However, the company now appears to be significantly undervalued when compared to the pipeline that it has in development. With the company expected to file an NDA soon and initiating another Phase III trial, the next year or so will provide a multitude of interesting catalysts that should help to drive share price growth. Coupled with the company's financial position, this share price increase should be sustainable and should be able to provide significant returns for long term oriented investors.

AEZS-130

AEZS-130 is a test developed by AEterna for the diagnosis...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details